EPGN.F Stock Overview
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Epigenomics AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.50 |
52 Week High | €0.93 |
52 Week Low | €0.50 |
Beta | 0.98 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -83.77% |
5 Year Change | -75.05% |
Change since IPO | -89.47% |
Recent News & Updates
Recent updates
Shareholder Returns
EPGN.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.0% | 1.2% |
1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how EPGN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how EPGN.F performed against the US Market.
Price Volatility
EPGN.F volatility | |
---|---|
EPGN.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EPGN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EPGN.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 18 | Noel Doheny | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
EPGN.F fundamental statistics | |
---|---|
Market cap | US$1.52m |
Earnings (TTM) | -US$17.63m |
Revenue (TTM) | US$483.71k |
3.1x
P/S Ratio-0.1x
P/E RatioIs EPGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EPGN.F income statement (TTM) | |
---|---|
Revenue | €447.00k |
Cost of Revenue | €105.00k |
Gross Profit | €342.00k |
Other Expenses | €16.63m |
Earnings | -€16.29m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 14, 2024
Earnings per share (EPS) | -19.09 |
Gross Margin | 76.51% |
Net Profit Margin | -3,644.52% |
Debt/Equity Ratio | 0% |
How did EPGN.F perform over the long term?
See historical performance and comparison